Aims: The study aimed to investigate the molecular mechanism of inhibition of proliferation and apoptosis induction by galangin against MCF-7 human breast cancer cells. Methods: Cell Counting Kit-8 assay was used to assess cell viability and flow cytometry was used to detect cell apoptosis. The expression level of apoptosis-related proteins (cleaved-caspase-9, cleaved-caspase-8, cleaved-caspase-3, Bad, cleaved-Bid, Bcl-2, Bax, p-phosphatidylinositol 3-kinase [PI3K], and p-Akt) and cell cycle-related proteins (cyclin D3, cyclin B1, cyclin-dependent kinases CDK1, CDK2, CDK4, p21, p27, p53) were evaluated by Western blotting. Results: Galangin increased the expression of Bax and decreased the expression of Bcl-2 in a concentration-dependent manner, inhibited cell viability, and induced apoptosis. Meanwhile, the expression of cleavage of caspase-9, caspase-8, caspase-3, Bid, and Bad increased significantly while the expression of p-PI3K and p-Akt proteins decreased. In addition, the protein levels of cyclin D3, cyclin B1, CDK1, CDK2, and CDK4 were downregulated while the expression levels of p21, p27, and p53 were upregulated significantly. Conclusion: Galangin could suppress the viability of MCF-7 cells and induce cell apoptosis via the mitochondrial pathway and PI3K/Akt inhibition as well as cell cycle arrest.

Keywords:
Galangin, MCF-7 human breast cancer cells, Apoptosis, Mitochondrial, Phosphatidylinositol 3-kinase/Akt, Cyclins, Cyclin-dependent kinases
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
2.
Rao CV, Reddy BS: NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004; 4: 29–42.
3.
Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ: Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012; 104: 1068–1079.
4.
Chinese Pharmacopoeia Commission: Pharmacopoeia of the People’s Republic of China, Beijing, China Med Sci Press, 2015, pp 287–288.
5.
Ha TK, Kim ME, Yoon JH, Bae SJ, Yeom J, Lee JS: Galangin induces human colon -cancer cell death via the mitochondrial dysfunction and caspase-dependent pathway. Exp Biol Med (Maywood) 2013; 238: 1047–1054.
6.
Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO, Chen YC: Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. J Funct Foods 2015; 15: 464–475.
7.
Zhang W, Lan Y, Huang Q, Hua Z: Galangin induces B16F10 melanoma cell apoptosis via mitochondrial pathway and sustained activation of p38 MAPK. Cytotechnology 2013; 65: 447–455.
8.
Lu YH, Lin-Tao, Wang ZT, Wei DZ, Xiang HB: Mechanism and inhibitory effect of galangin and its flavonoid mixture from Alpinia officinarum on mushroom tyrosinase and B16 murine melanoma cells. J Enzyme Inhib Med Chem 2007; 22: 433–438.
9.
Wang Y, Wu J, Lin B, Li X, Zhang H, Ding H, Chen X, Lan L, Luo H: Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway. Toxicology 2014; 326: 9–17.
10.
Zhang H, Li N, Wu J, Su L, Chen X, Lin B, Luo H: Galangin inhibits proliferation of HepG2 cells by activating AMPK via increasing the AMP/TAN ratio in a LKB1-independent manner. Eur J Pharmacol 2013; 718: 235–244.
11.
Zhang HT, Wu J, Wen M, Su LJ, Luo H: Galangin induces apoptosis in hepatocellular carcinoma cells through the caspase 8/t-Bid mitochondrial pathway. J Asian Nat Prod Res 2012; 14: 626–633.
12.
Wen M, Wu J, Luo H, Zhang H: Galangin induces autophagy through upregulation of p53 in HepG2 cells. Pharmacology 2012; 89: 247–255.
13.
Tolomeo M, Grimaudo S, Di Cristina A, Pipitone RM, Dusonchet L, Meli M, Crosta L, Gebbia N, Invidiata FP, Titone L, Simoni D: Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer lett 2008; 265: 289–297.
14.
So FV, Guthrie N, Chambers AF, Carroll KK: Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer lett 1997; 112: 127–133.
15.
Murray TJ, Yang X, Sherr DH: Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A. Breast Cancer Res 2006; 8:R17.
16.
Kirkin V, Joos S, Zörnig M: The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644: 229–249.
17.
Hatok J, Racay P: Bcl-2 family proteins: master regulators of cell survival. Biomol Concepts 2016; 7: 259–270.
18.
Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902–3907.
19.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988–1004.
20.
Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.
21.
Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006; 13: 137–144.
22.
Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005; 65: 10992–11000.
23.
Deshpande A, Sicinski P, Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene 2005; 24: 2909–2915.
24.
Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG: Cyclins and cell cycle control in cancer and disease. Genes Cancer 2012; 3: 649–657.
25.
Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S, Sasano H: Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2007; 98: 644–651.
26.
Yang J, Zhou Y, Cheng X, Fan Y, He S, Li S, Ye H, Xie C, Wu W, Li C, Pei H, Li L, Wei Z, Peng A, Wei Y, Li W, Chen L: Isogambogenic acid induces apoptosis-independent autophagic cell death in human non-small-cell lung carcinoma cells. Sci Rep 2015; 5: 7697.
27.
Ren K, Zhang W, Wu G, Ren J, Lu H, Li Z, Han X: Synergistic anti-cancer effects of galangin and berberine through apoptosis induction and proliferation inhibition in oesophageal carcinoma cells. Biomed Pharmacothe 2016; 84: 1748–1759.
28.
Zeng H, Huang P, Wang X, Wu J, Wu M, Huang J: Galangin-induced down-regulation of BACE1 by epigenetic mechanisms in SH-SY5Y cells. Neuroscience 2015; 294: 172–181.
29.
Xuan H, Li Z, Yan H, Sang Q, Wang K, He Q, Wang Y, Hu F: Antitumor activity of Chinese propolis in human breast cancer MCF-7 and MDA-MB-231 cells. Evid Based Complement Alternat Med 2014; 2014: 280120.
30.
Devadoss D, Ramar M, Chinnasamy A: Galangin, a dietary flavonol inhibits tumor initiation during experimental pulmonary tumorigenesis by modulating xenobiotic enzymes and antioxidant status. Arch Pharm Res 2018; 41: 265–275.
31.
Zhang W, Tang B, Huang Q, Hua Z: Galangin inhibits tumor growth and metastasis of B16F10 melanoma. J cell biochem 2013; 114: 152–161.
32.
Huh JE, Jung IT, Choi J, Baek YH, Lee JD, Park DS, Choi DY: The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages. Eur J Pharmacol 2013; 698: 57–66.
33.
Zhang HT, Luo H, Wu J, Lan LB, Fan DH, Zhu KD, Chen XY, Wen M, Liu HM: Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway. World J Gastroenterol 2010; 16: 3377–3384.
34.
Ciolino HP, Yeh GC: The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 1999; 79: 1340–1346.
35.
Green DR, Kroemer G: The pathophysiology of mitochondrial cell death. Science 2004; 305: 626–629.
36.
Borner C: The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39: 615–647.
37.
Catz SD, Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. oncogene 2001; 20: 7342–7351.
38.
Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491–501.
39.
Thompson JE, Thompson CB: Putting the rap on Akt. J Clin Oncol 2004; 22: 4217–4226.
40.
Atmaca H, Özkan AN, Zora M: Novel ferrocenyl pyrazoles inhibit breast cancer cell viability via induction of apoptosis and inhibition of PI3K/Akt and ERK1/2 signaling. Chem Biol Interact 2017; 263: 28–35.
41.
Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153–166.
42.
Choi YJ, Saez B, Anders L, Hydbring P, Stefano J, Bacon NA, Cook C, Kalaszczynska I, Signoretti S, Young RA, Scadden DT, Sicinski P: D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its Ligand FasL. Dev Cell 2014; 30: 255–267.
43.
Wong SC, Chan JK, Lee KC, Hsiao WL: Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Path 2001; 194: 35–42.
44.
Pirkmaier A, Dow R, Ganiatsas S, Waring P, Warren K, Thompson A, Hendley J, Germain D: Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 2003; 22: 4425–4433.
45.
Musgrove EA, Lee CS, Buckley MF, Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Nati Acad Sci U S A 1994; 91: 8022–8026.
46.
Tang L, Zhang Y, Pan H, Luo Q, Zhu XM, Dong MY, Leung PC, Sheng JZ, Huang HF: Involvement of cyclin B1 in progesterone-mediated cell growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell. Reprod Biol Endocrinol 2009; 7: 144–151.
47.
Ou Y, Ma L, Ma L, Huang Z, Zhou W, Zhao C, Zhang B, Song Y, Yu C, Zhan Q: Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer Biol Ther 2013; 14: 45–55.
48.
Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74.
49.
Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N: Combined immunohistochemistry of PLK1, p21, and p53 for predicting TP53 status: an independent prognostic factor of breast cancer. Am J Surg Pathol 2015; 39: 1026–1034.
50.
Walia V, Ding M, Kumar S, Nie D, Premkumar LS, Elble RC: hCLCA2 is a p53-inducible inhibitor of breast cancer cell proliferation. Cancer Res 2009; 69: 6624–6632.
51.
Langerød A1, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale AL, Jeffrey SS: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007; 9:R30.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.